Maxolon Starting Dose
The recommended starting dose of metoclopramide (Maxolon) for adults is 5 mg orally three times daily before meals, which can be titrated up to 10 mg three times daily based on symptom response and tolerability. 1
Dosing Algorithm
Oral Administration (Standard Use)
- Initial dose: 5 mg PO three times daily, taken 30 minutes before meals
- Titration: Increase gradually to 10 mg three times daily if needed and tolerated
- Maximum: 10 mg before each meal (30 mg/day total for standard dosing)
This low-dose initiation strategy is explicitly recommended by the 2025 AGA Clinical Practice Guideline on Management of Gastroparesis to improve tolerability and minimize adverse effects 1.
Alternative Formulations
- Intranasal metoclopramide: 15 mg before meals and at bedtime 1
- Intravenous/Intramuscular: 10 mg IV/IM for acute symptoms in diabetic gastroparesis 2
Critical Safety Considerations
Before prescribing, you must discuss the FDA black box warning regarding tardive dyskinesia risk with every patient. 1
High-Risk Populations
- Elderly patients: Higher risk of adverse events, start at 5 mg dose
- Patients on psychotropic agents: Increased risk of extrapyramidal symptoms and discontinuation
- Renal impairment (CrCl <40 mL/min): Start at approximately half the recommended dose 2
Monitoring Protocol
- Assess efficacy and adverse effects (particularly movement disorders) at 4-8 weeks 1
- Continue monitoring throughout treatment duration
- Consider drug holidays (1-4 weeks off every 8-12 weeks) to improve tolerability and reduce tardive dyskinesia risk 1
Context-Specific Dosing
Diabetic Gastroparesis (Severe Symptoms)
If severe symptoms are present, initiate with 10 mg IV/IM slowly over 1-2 minutes, then transition to oral therapy once symptoms improve 2.
Chemotherapy-Induced Nausea (High-Dose Protocol)
For highly emetogenic chemotherapy: 2 mg/kg IV (not the standard starting dose for routine use) 2, 3
Postoperative Nausea
10 mg IM/IV near end of surgery, though evidence suggests metoclopramide has limited efficacy for PONV prevention 2, 4
Common Pitfalls to Avoid
Do not start at 10 mg three times daily in treatment-naive patients - this increases risk of adverse effects and discontinuation. The guideline explicitly recommends starting at 5 mg 1.
Do not prescribe beyond 12 weeks continuously without reassessment - FDA warning due to tardive dyskinesia risk, though gastroparesis often requires chronic treatment 5.
Do not forget renal dose adjustment - metoclopramide is renally excreted; failure to adjust in renal impairment increases toxicity risk 2.
Do not overlook drug interactions - particularly with other dopamine antagonists or CNS depressants.
Evidence Quality Note
The 2025 AGA guideline provides a conditional recommendation with low certainty evidence for metoclopramide use in gastroparesis 1. Despite being the only FDA-approved medication for diabetic gastroparesis, the evidence base is limited, with most supporting studies from the 1980s. The guideline emphasizes shared decision-making, as patients who prioritize avoiding adverse effects over symptom improvement may reasonably decline metoclopramide 1.